| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 29 | 2026 | 1387 | 3.230 |
Why?
|
| Metabolomics | 18 | 2024 | 498 | 1.770 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 8 | 2026 | 101 | 1.720 |
Why?
|
| Mitochondria | 9 | 2026 | 760 | 1.600 |
Why?
|
| Urinary Bladder Neoplasms | 12 | 2026 | 492 | 1.520 |
Why?
|
| Androgens | 9 | 2023 | 265 | 1.500 |
Why?
|
| Cell Line, Tumor | 37 | 2026 | 3700 | 1.080 |
Why?
|
| Carbon | 2 | 2026 | 101 | 1.040 |
Why?
|
| Biomarkers, Tumor | 13 | 2019 | 1609 | 0.990 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2026 | 17 | 0.950 |
Why?
|
| Gene Expression Regulation, Neoplastic | 22 | 2026 | 2020 | 0.950 |
Why?
|
| Breast Neoplasms | 14 | 2024 | 2648 | 0.950 |
Why?
|
| Triple Negative Breast Neoplasms | 4 | 2025 | 280 | 0.940 |
Why?
|
| Persuasive Communication | 1 | 2025 | 11 | 0.910 |
Why?
|
| Protein Array Analysis | 9 | 2007 | 104 | 0.910 |
Why?
|
| Smoking Prevention | 1 | 2025 | 33 | 0.900 |
Why?
|
| Neoplasm Proteins | 9 | 2019 | 673 | 0.880 |
Why?
|
| DNA Repair | 4 | 2026 | 580 | 0.870 |
Why?
|
| Energy Metabolism | 5 | 2026 | 794 | 0.870 |
Why?
|
| Tumor Microenvironment | 4 | 2025 | 691 | 0.810 |
Why?
|
| Language | 1 | 2025 | 216 | 0.790 |
Why?
|
| Social Media | 1 | 2025 | 119 | 0.770 |
Why?
|
| Glucuronosyltransferase | 2 | 2022 | 63 | 0.750 |
Why?
|
| Hexosamines | 2 | 2026 | 17 | 0.730 |
Why?
|
| Sarcosine | 3 | 2013 | 8 | 0.720 |
Why?
|
| Adenocarcinoma | 3 | 2026 | 987 | 0.680 |
Why?
|
| Neoplasms | 7 | 2023 | 2956 | 0.670 |
Why?
|
| Metabolome | 12 | 2020 | 325 | 0.640 |
Why?
|
| DNA Methylation | 9 | 2026 | 1093 | 0.630 |
Why?
|
| Uridine Diphosphate Glucose Dehydrogenase | 1 | 2019 | 5 | 0.610 |
Why?
|
| Receptors, Estrogen | 4 | 2023 | 731 | 0.610 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2019 | 44 | 0.590 |
Why?
|
| Databases, Nucleic Acid | 1 | 2019 | 72 | 0.580 |
Why?
|
| Literacy | 1 | 2018 | 14 | 0.570 |
Why?
|
| Disease Progression | 11 | 2026 | 2202 | 0.570 |
Why?
|
| Receptors, Androgen | 8 | 2023 | 414 | 0.570 |
Why?
|
| Hyaluronic Acid | 1 | 2019 | 107 | 0.560 |
Why?
|
| Fatty Acids | 4 | 2026 | 378 | 0.530 |
Why?
|
| Humans | 91 | 2026 | 130776 | 0.500 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2025 | 815 | 0.500 |
Why?
|
| Cell Proliferation | 11 | 2026 | 2474 | 0.480 |
Why?
|
| Health Policy | 1 | 2018 | 225 | 0.480 |
Why?
|
| Epigenesis, Genetic | 5 | 2026 | 773 | 0.470 |
Why?
|
| Neuroendocrine Tumors | 1 | 2016 | 70 | 0.450 |
Why?
|
| Poverty | 1 | 2018 | 454 | 0.440 |
Why?
|
| Proteomics | 6 | 2015 | 605 | 0.440 |
Why?
|
| Proto-Oncogene Proteins c-myc | 4 | 2024 | 193 | 0.440 |
Why?
|
| Hormones | 1 | 2015 | 163 | 0.430 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2014 | 12 | 0.430 |
Why?
|
| Male | 48 | 2026 | 64680 | 0.410 |
Why?
|
| Animals | 41 | 2026 | 33891 | 0.380 |
Why?
|
| Cigarette Smoking | 2 | 2026 | 95 | 0.350 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 2011 | 10 | 0.340 |
Why?
|
| Prostate | 6 | 2018 | 408 | 0.340 |
Why?
|
| Mass Spectrometry | 8 | 2019 | 363 | 0.330 |
Why?
|
| Digital Rectal Examination | 1 | 2010 | 4 | 0.330 |
Why?
|
| Amino Acids | 2 | 2019 | 566 | 0.320 |
Why?
|
| Transcriptome | 7 | 2025 | 1130 | 0.310 |
Why?
|
| Spermatozoa | 3 | 2010 | 254 | 0.300 |
Why?
|
| Signal Transduction | 12 | 2026 | 4670 | 0.300 |
Why?
|
| Nuclear Receptor Coactivator 2 | 3 | 2015 | 148 | 0.290 |
Why?
|
| Tissue Array Analysis | 3 | 2019 | 135 | 0.290 |
Why?
|
| Glutamine | 4 | 2024 | 204 | 0.280 |
Why?
|
| Mice | 26 | 2025 | 18208 | 0.270 |
Why?
|
| Autoantibodies | 3 | 2005 | 438 | 0.260 |
Why?
|
| Gene Knockdown Techniques | 4 | 2019 | 378 | 0.260 |
Why?
|
| Oncogenes | 2 | 2019 | 164 | 0.260 |
Why?
|
| Antibody Formation | 1 | 2007 | 227 | 0.260 |
Why?
|
| Female | 30 | 2025 | 70630 | 0.250 |
Why?
|
| Promoter Regions, Genetic | 5 | 2019 | 1213 | 0.250 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2019 | 996 | 0.240 |
Why?
|
| Gene Expression Profiling | 8 | 2020 | 1843 | 0.240 |
Why?
|
| RNA Stability | 2 | 2024 | 75 | 0.240 |
Why?
|
| Fatty Acid Synthase, Type I | 1 | 2026 | 17 | 0.240 |
Why?
|
| Oxidative Phosphorylation | 2 | 2024 | 129 | 0.240 |
Why?
|
| Biosynthetic Pathways | 1 | 2026 | 32 | 0.240 |
Why?
|
| Antibodies | 3 | 2005 | 317 | 0.240 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2019 | 258 | 0.240 |
Why?
|
| RNA, Long Noncoding | 2 | 2019 | 228 | 0.240 |
Why?
|
| Antigens, Protozoan | 2 | 2017 | 78 | 0.240 |
Why?
|
| Plasmodium falciparum | 2 | 2017 | 93 | 0.230 |
Why?
|
| Smoke | 1 | 2026 | 81 | 0.230 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2025 | 19 | 0.230 |
Why?
|
| DNA Adducts | 2 | 2023 | 71 | 0.230 |
Why?
|
| Cell Line | 7 | 2020 | 2569 | 0.230 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2017 | 161 | 0.230 |
Why?
|
| Cytoskeleton | 1 | 2026 | 167 | 0.220 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2025 | 41 | 0.220 |
Why?
|
| Mitochondrial Proteins | 3 | 2017 | 277 | 0.220 |
Why?
|
| Pancreatic Neoplasms | 1 | 2011 | 743 | 0.220 |
Why?
|
| Apoptosis | 10 | 2025 | 1852 | 0.220 |
Why?
|
| Glutaminase | 1 | 2024 | 18 | 0.210 |
Why?
|
| Urinary Bladder | 2 | 2019 | 220 | 0.210 |
Why?
|
| Ribonucleotides | 1 | 2024 | 31 | 0.210 |
Why?
|
| Natural Language Processing | 1 | 2025 | 78 | 0.210 |
Why?
|
| Racemases and Epimerases | 1 | 2004 | 12 | 0.210 |
Why?
|
| Trust | 1 | 2025 | 88 | 0.210 |
Why?
|
| Chick Embryo | 2 | 2026 | 125 | 0.210 |
Why?
|
| Macrophages | 3 | 2025 | 651 | 0.210 |
Why?
|
| Proteome | 4 | 2011 | 287 | 0.210 |
Why?
|
| Spermatogenesis | 1 | 2005 | 168 | 0.210 |
Why?
|
| Isocitrate Dehydrogenase | 3 | 2020 | 78 | 0.210 |
Why?
|
| Cell Movement | 2 | 2026 | 871 | 0.210 |
Why?
|
| Membrane Transport Proteins | 1 | 2005 | 181 | 0.210 |
Why?
|
| Fear | 1 | 2025 | 194 | 0.200 |
Why?
|
| Neoplasm Invasiveness | 6 | 2019 | 631 | 0.200 |
Why?
|
| Pyrimidines | 2 | 2026 | 450 | 0.200 |
Why?
|
| T-Lymphocytes | 2 | 2025 | 1692 | 0.190 |
Why?
|
| Transcription, Genetic | 4 | 2019 | 1382 | 0.190 |
Why?
|
| Uridine Diphosphate | 1 | 2022 | 4 | 0.190 |
Why?
|
| Neoplastic Processes | 1 | 2022 | 6 | 0.190 |
Why?
|
| MicroRNAs | 1 | 2009 | 899 | 0.190 |
Why?
|
| Antigens | 1 | 2002 | 104 | 0.190 |
Why?
|
| Sperm Capacitation | 3 | 2010 | 20 | 0.190 |
Why?
|
| Chromatography, Liquid | 7 | 2019 | 238 | 0.180 |
Why?
|
| Nod2 Signaling Adaptor Protein | 2 | 2012 | 21 | 0.180 |
Why?
|
| Biomarkers | 5 | 2016 | 3400 | 0.180 |
Why?
|
| Interleukin-6 | 1 | 2024 | 414 | 0.180 |
Why?
|
| Proteogenomics | 1 | 2023 | 110 | 0.180 |
Why?
|
| Pyruvic Acid | 2 | 2018 | 35 | 0.180 |
Why?
|
| Isotope Labeling | 2 | 2013 | 94 | 0.180 |
Why?
|
| Oxidative Stress | 2 | 2018 | 803 | 0.180 |
Why?
|
| Smoking | 2 | 2017 | 926 | 0.170 |
Why?
|
| Autophagy | 2 | 2016 | 422 | 0.170 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 2 | 2019 | 70 | 0.170 |
Why?
|
| Immunohistochemistry | 5 | 2014 | 1593 | 0.170 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2019 | 144 | 0.170 |
Why?
|
| Neuropeptide Y | 1 | 2020 | 34 | 0.170 |
Why?
|
| Mice, SCID | 3 | 2016 | 578 | 0.160 |
Why?
|
| Alcohol Oxidoreductases | 2 | 2017 | 18 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 7 | 2019 | 962 | 0.160 |
Why?
|
| Antimalarials | 2 | 2017 | 47 | 0.160 |
Why?
|
| Insulin-Secreting Cells | 1 | 2021 | 136 | 0.160 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2020 | 57 | 0.160 |
Why?
|
| Antihypertensive Agents | 1 | 2023 | 421 | 0.160 |
Why?
|
| Inactivation, Metabolic | 1 | 2019 | 26 | 0.160 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2020 | 606 | 0.150 |
Why?
|
| Uridine Diphosphate Glucuronic Acid | 1 | 2019 | 6 | 0.150 |
Why?
|
| Aldehyde Oxidase | 1 | 2019 | 7 | 0.150 |
Why?
|
| Botulinum Toxins, Type A | 2 | 2020 | 126 | 0.150 |
Why?
|
| Chorioallantoic Membrane | 1 | 2019 | 12 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2016 | 479 | 0.150 |
Why?
|
| Antigen Presentation | 1 | 2019 | 112 | 0.150 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2019 | 28 | 0.150 |
Why?
|
| PPAR gamma | 1 | 2019 | 87 | 0.150 |
Why?
|
| RNA, Messenger | 6 | 2023 | 2558 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2015 | 1218 | 0.150 |
Why?
|
| Tumor Escape | 1 | 2019 | 62 | 0.150 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2021 | 243 | 0.150 |
Why?
|
| Medicalization | 1 | 2018 | 1 | 0.150 |
Why?
|
| Myeloid Cells | 1 | 2019 | 112 | 0.140 |
Why?
|
| Colonic Neoplasms | 1 | 2001 | 265 | 0.140 |
Why?
|
| Reproducibility of Results | 5 | 2012 | 2937 | 0.140 |
Why?
|
| DNA Damage | 2 | 2023 | 519 | 0.140 |
Why?
|
| Colitis | 1 | 2020 | 163 | 0.140 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2020 | 153 | 0.140 |
Why?
|
| CpG Islands | 1 | 2019 | 340 | 0.140 |
Why?
|
| Metabolic Flux Analysis | 2 | 2019 | 12 | 0.140 |
Why?
|
| Hematopoiesis | 1 | 2020 | 212 | 0.140 |
Why?
|
| Glucose Transport Proteins, Facilitative | 1 | 2018 | 22 | 0.140 |
Why?
|
| Immunoblotting | 4 | 2009 | 291 | 0.140 |
Why?
|
| Blotting, Western | 4 | 2015 | 1012 | 0.140 |
Why?
|
| Extracellular Matrix | 1 | 2019 | 229 | 0.140 |
Why?
|
| Chloroquine | 1 | 2017 | 31 | 0.140 |
Why?
|
| Social Environment | 1 | 2018 | 117 | 0.140 |
Why?
|
| Cell Dedifferentiation | 1 | 2017 | 21 | 0.140 |
Why?
|
| Glutarates | 2 | 2017 | 38 | 0.140 |
Why?
|
| Deoxyribonucleases | 2 | 2012 | 21 | 0.140 |
Why?
|
| Breast | 1 | 2019 | 216 | 0.140 |
Why?
|
| Denervation | 1 | 2017 | 23 | 0.130 |
Why?
|
| Transcription Factors | 3 | 2016 | 2440 | 0.130 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Kinase | 1 | 2018 | 54 | 0.130 |
Why?
|
| Multiprotein Complexes | 2 | 2016 | 194 | 0.130 |
Why?
|
| Mice, Nude | 6 | 2019 | 708 | 0.130 |
Why?
|
| Mutagens | 1 | 2017 | 47 | 0.130 |
Why?
|
| Disease Models, Animal | 8 | 2020 | 4664 | 0.130 |
Why?
|
| Colon | 1 | 2020 | 356 | 0.130 |
Why?
|
| Homeodomain Proteins | 2 | 2021 | 568 | 0.130 |
Why?
|
| Phosphorylation | 6 | 2019 | 1568 | 0.130 |
Why?
|
| Carcinogens | 1 | 2017 | 128 | 0.130 |
Why?
|
| Intestinal Mucosa | 2 | 2012 | 768 | 0.130 |
Why?
|
| Histones | 4 | 2026 | 542 | 0.130 |
Why?
|
| Chemical Fractionation | 2 | 2007 | 15 | 0.130 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 22 | 0.130 |
Why?
|
| Ketoglutarate Dehydrogenase Complex | 1 | 2016 | 13 | 0.130 |
Why?
|
| Tobacco Products | 1 | 2017 | 60 | 0.130 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2014 | 1007 | 0.130 |
Why?
|
| Phospholipids | 1 | 2017 | 103 | 0.120 |
Why?
|
| Hematologic Neoplasms | 1 | 2020 | 312 | 0.120 |
Why?
|
| Metalloendopeptidases | 1 | 2016 | 101 | 0.120 |
Why?
|
| NF-kappa B | 5 | 2020 | 449 | 0.120 |
Why?
|
| Cisplatin | 1 | 2018 | 273 | 0.120 |
Why?
|
| Cellular Reprogramming | 1 | 2017 | 128 | 0.120 |
Why?
|
| Models, Biological | 3 | 2011 | 1391 | 0.120 |
Why?
|
| Health Status | 1 | 2018 | 385 | 0.120 |
Why?
|
| Trans-Activators | 2 | 2021 | 683 | 0.120 |
Why?
|
| Models, Theoretical | 1 | 2018 | 363 | 0.120 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 1307 | 0.120 |
Why?
|
| Clonal Evolution | 1 | 2016 | 47 | 0.120 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2016 | 40 | 0.120 |
Why?
|
| Middle Aged | 12 | 2024 | 28499 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 231 | 0.120 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 2015 | 15 | 0.120 |
Why?
|
| Neovascularization, Physiologic | 1 | 2017 | 198 | 0.120 |
Why?
|
| Hemocyanins | 1 | 2015 | 23 | 0.120 |
Why?
|
| Circadian Clocks | 1 | 2016 | 86 | 0.120 |
Why?
|
| src-Family Kinases | 1 | 2016 | 92 | 0.120 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2018 | 210 | 0.120 |
Why?
|
| Monophenol Monooxygenase | 1 | 2015 | 25 | 0.110 |
Why?
|
| Benzhydryl Compounds | 1 | 2016 | 76 | 0.110 |
Why?
|
| GA-Binding Protein Transcription Factor | 1 | 2015 | 5 | 0.110 |
Why?
|
| Case-Control Studies | 6 | 2019 | 3418 | 0.110 |
Why?
|
| Polymers | 1 | 2016 | 111 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 364 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 1325 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 375 | 0.110 |
Why?
|
| Phenols | 1 | 2015 | 71 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2016 | 599 | 0.110 |
Why?
|
| Plasma Cells | 1 | 2015 | 55 | 0.110 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 435 | 0.110 |
Why?
|
| Molecular Docking Simulation | 1 | 2015 | 150 | 0.110 |
Why?
|
| Data Compression | 1 | 2014 | 11 | 0.110 |
Why?
|
| In Vitro Techniques | 2 | 2014 | 809 | 0.110 |
Why?
|
| Glucose | 2 | 2018 | 848 | 0.110 |
Why?
|
| Acrosome Reaction | 2 | 2005 | 11 | 0.110 |
Why?
|
| Hypertension | 1 | 2023 | 1356 | 0.110 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2016 | 427 | 0.110 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 345 | 0.110 |
Why?
|
| Organ Specificity | 2 | 2014 | 397 | 0.110 |
Why?
|
| Triglycerides | 1 | 2017 | 605 | 0.110 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2016 | 198 | 0.110 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2016 | 326 | 0.110 |
Why?
|
| Hyperargininemia | 1 | 2014 | 13 | 0.110 |
Why?
|
| Retinal Neurons | 1 | 2014 | 15 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 493 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2005 | 784 | 0.100 |
Why?
|
| Immunotherapy | 1 | 2019 | 755 | 0.100 |
Why?
|
| Polyamines | 1 | 2014 | 37 | 0.100 |
Why?
|
| Arginase | 1 | 2014 | 35 | 0.100 |
Why?
|
| Orchiectomy | 1 | 2013 | 48 | 0.100 |
Why?
|
| Phosphofructokinase-2 | 1 | 2013 | 22 | 0.100 |
Why?
|
| Alternative Splicing | 1 | 2015 | 309 | 0.100 |
Why?
|
| Sarcosine Dehydrogenase | 2 | 2013 | 2 | 0.100 |
Why?
|
| Glycine N-Methyltransferase | 2 | 2013 | 5 | 0.100 |
Why?
|
| Cells, Cultured | 4 | 2021 | 2905 | 0.100 |
Why?
|
| Carbon Isotopes | 1 | 2013 | 230 | 0.100 |
Why?
|
| Retinopathy of Prematurity | 1 | 2014 | 64 | 0.100 |
Why?
|
| Phosphates | 1 | 2013 | 109 | 0.100 |
Why?
|
| Prognosis | 4 | 2017 | 4934 | 0.100 |
Why?
|
| Decision Making | 1 | 2018 | 690 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2021 | 872 | 0.100 |
Why?
|
| Retinal Degeneration | 1 | 2014 | 98 | 0.100 |
Why?
|
| Abortion, Spontaneous | 1 | 2013 | 82 | 0.100 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 2015 | 329 | 0.090 |
Why?
|
| Sensitivity and Specificity | 7 | 2006 | 2126 | 0.090 |
Why?
|
| Multiple Myeloma | 1 | 2015 | 190 | 0.090 |
Why?
|
| Pandemics | 1 | 2020 | 1158 | 0.090 |
Why?
|
| Tamoxifen | 1 | 2014 | 351 | 0.090 |
Why?
|
| Metabolic Networks and Pathways | 3 | 2019 | 193 | 0.090 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinase 2 | 1 | 2012 | 7 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2014 | 252 | 0.090 |
Why?
|
| Blood Platelets | 1 | 2015 | 317 | 0.090 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 681 | 0.090 |
Why?
|
| Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing) | 1 | 2012 | 7 | 0.090 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 695 | 0.090 |
Why?
|
| Dihydroorotase | 1 | 2012 | 7 | 0.090 |
Why?
|
| Aspartate Carbamoyltransferase | 1 | 2012 | 7 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 755 | 0.090 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2020 | 834 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 1 | 2018 | 636 | 0.090 |
Why?
|
| Carcinoembryonic Antigen | 2 | 2002 | 25 | 0.090 |
Why?
|
| Neoplasm Transplantation | 4 | 2016 | 357 | 0.090 |
Why?
|
| Hyperoxia | 1 | 2014 | 135 | 0.090 |
Why?
|
| Melanoma | 1 | 2019 | 920 | 0.090 |
Why?
|
| Glycolysis | 3 | 2018 | 172 | 0.090 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2011 | 30 | 0.090 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 41 | 0.090 |
Why?
|
| Sperm Motility | 2 | 2010 | 113 | 0.090 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2016 | 407 | 0.090 |
Why?
|
| Cricetinae | 3 | 2010 | 363 | 0.090 |
Why?
|
| Circadian Rhythm | 1 | 2014 | 315 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 1076 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2019 | 733 | 0.080 |
Why?
|
| Cell Differentiation | 2 | 2021 | 1919 | 0.080 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2011 | 82 | 0.080 |
Why?
|
| Methylation | 1 | 2011 | 197 | 0.080 |
Why?
|
| Gene Expression Regulation | 5 | 2021 | 2341 | 0.080 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 545 | 0.080 |
Why?
|
| Drosophila Proteins | 1 | 2016 | 785 | 0.080 |
Why?
|
| MAP Kinase Signaling System | 1 | 2012 | 304 | 0.080 |
Why?
|
| Prostatic Hyperplasia | 2 | 2008 | 115 | 0.080 |
Why?
|
| Lymphoma, Follicular | 1 | 2010 | 32 | 0.080 |
Why?
|
| Epithelial Cells | 2 | 2012 | 899 | 0.080 |
Why?
|
| GTP Phosphohydrolases | 1 | 2011 | 160 | 0.080 |
Why?
|
| Flagella | 1 | 2010 | 27 | 0.080 |
Why?
|
| Oxidation-Reduction | 3 | 2016 | 432 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 2 | 2015 | 234 | 0.080 |
Why?
|
| Microtubule Proteins | 1 | 2010 | 28 | 0.080 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2011 | 249 | 0.080 |
Why?
|
| Liver Neoplasms | 2 | 2019 | 1398 | 0.080 |
Why?
|
| Inflammation | 2 | 2015 | 1490 | 0.080 |
Why?
|
| Amino Acyl-tRNA Synthetases | 1 | 2009 | 26 | 0.080 |
Why?
|
| Survival Analysis | 3 | 2019 | 1512 | 0.080 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 1790 | 0.080 |
Why?
|
| Testosterone | 1 | 2015 | 598 | 0.080 |
Why?
|
| Liver Cirrhosis | 1 | 2016 | 909 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 1307 | 0.080 |
Why?
|
| Hydroxamic Acids | 1 | 2009 | 59 | 0.070 |
Why?
|
| DNA-Binding Proteins | 2 | 2009 | 1950 | 0.070 |
Why?
|
| Mutation | 2 | 2020 | 6145 | 0.070 |
Why?
|
| Heat-Shock Proteins | 1 | 2010 | 175 | 0.070 |
Why?
|
| Computer Simulation | 1 | 2012 | 680 | 0.070 |
Why?
|
| Pentose Phosphate Pathway | 2 | 2019 | 44 | 0.070 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 3 | 2018 | 59 | 0.070 |
Why?
|
| Crohn Disease | 1 | 2012 | 291 | 0.070 |
Why?
|
| Lung Neoplasms | 2 | 2018 | 1538 | 0.070 |
Why?
|
| Adenosine | 1 | 2009 | 123 | 0.070 |
Why?
|
| Aged | 7 | 2018 | 20958 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2011 | 6784 | 0.070 |
Why?
|
| Copper | 1 | 2008 | 72 | 0.070 |
Why?
|
| Adult | 6 | 2021 | 31269 | 0.070 |
Why?
|
| Positive Transcriptional Elongation Factor B | 1 | 2007 | 17 | 0.070 |
Why?
|
| Prostate-Specific Antigen | 2 | 2008 | 227 | 0.070 |
Why?
|
| Lipids | 2 | 2023 | 563 | 0.070 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2016 | 1005 | 0.070 |
Why?
|
| Neoplasm Grading | 2 | 2019 | 273 | 0.070 |
Why?
|
| Enzyme Inhibitors | 4 | 2014 | 564 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2016 | 651 | 0.060 |
Why?
|
| Collodion | 2 | 2004 | 8 | 0.060 |
Why?
|
| Methyltransferases | 1 | 2007 | 77 | 0.060 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2007 | 121 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 4 | 2019 | 4695 | 0.060 |
Why?
|
| Liver | 3 | 2023 | 1802 | 0.060 |
Why?
|
| Glucosamine 6-Phosphate N-Acetyltransferase | 1 | 2026 | 1 | 0.060 |
Why?
|
| Protein Binding | 3 | 2018 | 1660 | 0.060 |
Why?
|
| Genomics | 1 | 2014 | 1622 | 0.060 |
Why?
|
| Young Adult | 3 | 2020 | 10021 | 0.060 |
Why?
|
| Leukemia, B-Cell | 1 | 2006 | 25 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2006 | 87 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2006 | 92 | 0.060 |
Why?
|
| Rats | 2 | 2023 | 3411 | 0.060 |
Why?
|
| MCF-7 Cells | 2 | 2017 | 209 | 0.060 |
Why?
|
| Carcinogenesis | 2 | 2020 | 351 | 0.060 |
Why?
|
| Sperm-Ovum Interactions | 1 | 2005 | 22 | 0.060 |
Why?
|
| Peptide Library | 1 | 2005 | 56 | 0.060 |
Why?
|
| Homeostasis | 3 | 2016 | 712 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2006 | 96 | 0.060 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2006 | 42 | 0.060 |
Why?
|
| Spermatids | 1 | 2005 | 25 | 0.060 |
Why?
|
| Trisomy | 1 | 2006 | 112 | 0.060 |
Why?
|
| Acrosome | 1 | 2005 | 15 | 0.060 |
Why?
|
| Metribolone | 2 | 2018 | 28 | 0.060 |
Why?
|
| Algorithms | 1 | 2012 | 1677 | 0.060 |
Why?
|
| Nuclear Proteins | 2 | 2009 | 1218 | 0.060 |
Why?
|
| Tumor Burden | 2 | 2017 | 239 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2010 | 1729 | 0.050 |
Why?
|
| Electron Transport Complex I | 1 | 2024 | 31 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2019 | 288 | 0.050 |
Why?
|
| Catalytic Domain | 2 | 2015 | 159 | 0.050 |
Why?
|
| Cohort Studies | 4 | 2019 | 5089 | 0.050 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2025 | 141 | 0.050 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2001 | 163 | 0.050 |
Why?
|
| SMARCB1 Protein | 1 | 2024 | 42 | 0.050 |
Why?
|
| Biological Transport | 2 | 2018 | 332 | 0.050 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 661 | 0.050 |
Why?
|
| Translocation, Genetic | 1 | 2006 | 349 | 0.050 |
Why?
|
| Morpholines | 1 | 2004 | 68 | 0.050 |
Why?
|
| Enzyme Activation | 2 | 2017 | 586 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2006 | 430 | 0.050 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2003 | 40 | 0.050 |
Why?
|
| Genome, Human | 1 | 2010 | 1323 | 0.050 |
Why?
|
| Taurine | 1 | 2023 | 11 | 0.050 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2009 | 578 | 0.050 |
Why?
|
| Pentoxifylline | 1 | 2003 | 20 | 0.050 |
Why?
|
| NFI Transcription Factors | 1 | 2023 | 50 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 89 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 528 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 1840 | 0.050 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2003 | 54 | 0.050 |
Why?
|
| Acetylation | 1 | 2023 | 182 | 0.050 |
Why?
|
| Neurofibromin 1 | 1 | 2023 | 58 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2017 | 975 | 0.050 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2015 | 64 | 0.050 |
Why?
|
| Macromolecular Substances | 1 | 2002 | 129 | 0.050 |
Why?
|
| United States | 1 | 2018 | 11834 | 0.050 |
Why?
|
| ROC Curve | 2 | 2018 | 615 | 0.050 |
Why?
|
| Nucleoside Deaminases | 1 | 2002 | 23 | 0.050 |
Why?
|
| Mutagenesis | 1 | 2023 | 331 | 0.050 |
Why?
|
| Peptides | 1 | 2005 | 710 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 1 | 2024 | 231 | 0.040 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2001 | 9 | 0.040 |
Why?
|
| Antibodies, Neoplasm | 1 | 2001 | 54 | 0.040 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2001 | 28 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2001 | 72 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2023 | 618 | 0.040 |
Why?
|
| Phenotype | 1 | 2011 | 4479 | 0.040 |
Why?
|
| Time Factors | 4 | 2018 | 6241 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2008 | 1605 | 0.040 |
Why?
|
| Equipment Design | 1 | 2002 | 547 | 0.040 |
Why?
|
| Interferons | 1 | 2001 | 136 | 0.040 |
Why?
|
| Bile Acids and Salts | 1 | 2023 | 259 | 0.040 |
Why?
|
| Radiation Tolerance | 1 | 2020 | 61 | 0.040 |
Why?
|
| Germ-Free Life | 1 | 2020 | 61 | 0.040 |
Why?
|
| Glucuronic Acid | 1 | 2019 | 14 | 0.040 |
Why?
|
| S-Adenosylhomocysteine | 1 | 2019 | 16 | 0.040 |
Why?
|
| Pancreas | 1 | 2021 | 227 | 0.040 |
Why?
|
| S-Adenosylmethionine | 1 | 2019 | 27 | 0.040 |
Why?
|
| Nervous System | 1 | 2020 | 122 | 0.040 |
Why?
|
| Proteins | 2 | 2003 | 1006 | 0.040 |
Why?
|
| Cytokines | 3 | 2017 | 1339 | 0.040 |
Why?
|
| Immunoprecipitation | 2 | 2012 | 189 | 0.040 |
Why?
|
| NADP | 1 | 2019 | 54 | 0.040 |
Why?
|
| Kynurenine | 1 | 2019 | 26 | 0.040 |
Why?
|
| Granulocytes | 1 | 2019 | 68 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2001 | 412 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 788 | 0.040 |
Why?
|
| Tryptophan | 1 | 2019 | 85 | 0.040 |
Why?
|
| Nucleotides | 1 | 2019 | 90 | 0.040 |
Why?
|
| Reactive Oxygen Species | 2 | 2017 | 517 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2020 | 3831 | 0.040 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2019 | 51 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2001 | 642 | 0.040 |
Why?
|
| Gene Expression | 2 | 2013 | 1489 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2016 | 356 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2001 | 401 | 0.040 |
Why?
|
| Protein Biosynthesis | 1 | 2001 | 575 | 0.040 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2018 | 36 | 0.040 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2019 | 159 | 0.040 |
Why?
|
| Kinetics | 2 | 2015 | 1087 | 0.040 |
Why?
|
| Ubiquitination | 1 | 2019 | 174 | 0.040 |
Why?
|
| Adolescent | 2 | 2020 | 20832 | 0.040 |
Why?
|
| Syndrome | 1 | 2021 | 1161 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2018 | 49 | 0.030 |
Why?
|
| Cell Survival | 2 | 2015 | 839 | 0.030 |
Why?
|
| Mice, Transgenic | 2 | 2018 | 2341 | 0.030 |
Why?
|
| Citric Acid Cycle | 1 | 2018 | 43 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2017 | 85 | 0.030 |
Why?
|
| Butanones | 1 | 2017 | 7 | 0.030 |
Why?
|
| Acetylcholine Release Inhibitors | 1 | 2017 | 17 | 0.030 |
Why?
|
| Nitrosamines | 1 | 2017 | 15 | 0.030 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2017 | 25 | 0.030 |
Why?
|
| Benzo(a)pyrene | 1 | 2017 | 24 | 0.030 |
Why?
|
| Adenoma | 1 | 2019 | 145 | 0.030 |
Why?
|
| Azacitidine | 1 | 2017 | 52 | 0.030 |
Why?
|
| Axons | 1 | 2020 | 388 | 0.030 |
Why?
|
| Nitrogenous Group Transferases | 1 | 2017 | 4 | 0.030 |
Why?
|
| Phosphatidylethanolamines | 1 | 2017 | 22 | 0.030 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2009 | 165 | 0.030 |
Why?
|
| Pericytes | 1 | 2017 | 18 | 0.030 |
Why?
|
| Lactic Acid | 1 | 2018 | 147 | 0.030 |
Why?
|
| Malaria, Falciparum | 1 | 2017 | 67 | 0.030 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2017 | 14 | 0.030 |
Why?
|
| Diglycerides | 1 | 2017 | 16 | 0.030 |
Why?
|
| Phosphorylcholine | 1 | 2017 | 31 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 3417 | 0.030 |
Why?
|
| Neutrophils | 1 | 2019 | 364 | 0.030 |
Why?
|
| Lysophospholipids | 1 | 2017 | 39 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2017 | 247 | 0.030 |
Why?
|
| Glutathione Transferase | 1 | 2017 | 146 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2002 | 718 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2017 | 82 | 0.030 |
Why?
|
| Ketoglutaric Acids | 1 | 2016 | 23 | 0.030 |
Why?
|
| Phosphatidylserines | 1 | 2017 | 46 | 0.030 |
Why?
|
| Mesocricetus | 2 | 2010 | 66 | 0.030 |
Why?
|
| Janus Kinases | 1 | 2017 | 34 | 0.030 |
Why?
|
| Capillary Permeability | 1 | 2017 | 72 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 285 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2019 | 301 | 0.030 |
Why?
|
| Protein Stability | 1 | 2017 | 166 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2017 | 153 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 2017 | 75 | 0.030 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2016 | 31 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2017 | 212 | 0.030 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 1 | 2017 | 79 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 823 | 0.030 |
Why?
|
| Th1 Cells | 1 | 2017 | 156 | 0.030 |
Why?
|
| Lysine | 1 | 2016 | 165 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2017 | 340 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2016 | 178 | 0.030 |
Why?
|
| Molecular Chaperones | 1 | 2016 | 172 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 418 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2018 | 379 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2017 | 235 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2017 | 198 | 0.030 |
Why?
|
| Octopodiformes | 1 | 2015 | 1 | 0.030 |
Why?
|
| Enzyme Assays | 1 | 2015 | 11 | 0.030 |
Why?
|
| Microscopy | 1 | 2016 | 118 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2015 | 156 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2018 | 317 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2016 | 115 | 0.030 |
Why?
|
| Thermodynamics | 1 | 2015 | 147 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2017 | 361 | 0.030 |
Why?
|
| Bortezomib | 1 | 2015 | 71 | 0.030 |
Why?
|
| Thalidomide | 1 | 2015 | 39 | 0.030 |
Why?
|
| Protein Structure, Secondary | 1 | 2015 | 238 | 0.030 |
Why?
|
| Boronic Acids | 1 | 2015 | 49 | 0.030 |
Why?
|
| Nicotine | 1 | 2015 | 117 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2015 | 205 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2017 | 627 | 0.030 |
Why?
|
| Hemin | 1 | 2014 | 14 | 0.030 |
Why?
|
| Artemisinins | 1 | 2014 | 12 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2017 | 539 | 0.030 |
Why?
|
| Pyrazines | 1 | 2015 | 79 | 0.030 |
Why?
|
| Lipogenesis | 1 | 2015 | 62 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2015 | 126 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2015 | 363 | 0.030 |
Why?
|
| User-Computer Interface | 1 | 2015 | 158 | 0.030 |
Why?
|
| Oxidoreductases Acting on CH-NH Group Donors | 1 | 2014 | 25 | 0.030 |
Why?
|
| CLOCK Proteins | 1 | 2014 | 34 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2017 | 372 | 0.030 |
Why?
|
| Ligands | 1 | 2015 | 486 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2015 | 555 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 2849 | 0.030 |
Why?
|
| ARNTL Transcription Factors | 1 | 2014 | 46 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 2145 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2015 | 290 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 715 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2015 | 235 | 0.030 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2013 | 61 | 0.030 |
Why?
|
| Glioma | 1 | 2018 | 505 | 0.030 |
Why?
|
| Sarcosine Oxidase | 1 | 2013 | 1 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2015 | 253 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2017 | 518 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 418 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2015 | 252 | 0.020 |
Why?
|
| Neurodegenerative Diseases | 1 | 2016 | 288 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2015 | 688 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2015 | 562 | 0.020 |
Why?
|
| Caenorhabditis elegans | 1 | 2015 | 251 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 2307 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 701 | 0.020 |
Why?
|
| Up-Regulation | 2 | 2008 | 829 | 0.020 |
Why?
|
| MAP Kinase Kinase Kinase 4 | 1 | 2012 | 2 | 0.020 |
Why?
|
| Decidua | 1 | 2013 | 139 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2006 | 770 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2016 | 360 | 0.020 |
Why?
|
| Neuroprotective Agents | 1 | 2014 | 160 | 0.020 |
Why?
|
| Salmonella typhimurium | 1 | 2012 | 43 | 0.020 |
Why?
|
| Wnt Signaling Pathway | 1 | 2013 | 212 | 0.020 |
Why?
|
| Salmonella Infections | 1 | 2012 | 31 | 0.020 |
Why?
|
| Protein Phosphatase 2 | 1 | 2012 | 33 | 0.020 |
Why?
|
| Drosophila | 1 | 2016 | 791 | 0.020 |
Why?
|
| Salmonella | 1 | 2012 | 31 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 124 | 0.020 |
Why?
|
| Computational Biology | 1 | 2017 | 867 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2013 | 306 | 0.020 |
Why?
|
| Embryo Implantation | 1 | 2013 | 216 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2015 | 381 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2014 | 747 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2015 | 2397 | 0.020 |
Why?
|
| Dynamins | 1 | 2011 | 44 | 0.020 |
Why?
|
| Drosophila melanogaster | 1 | 2016 | 850 | 0.020 |
Why?
|
| Sulfites | 1 | 2010 | 27 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 3488 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2014 | 1016 | 0.020 |
Why?
|
| Axoneme | 1 | 2010 | 7 | 0.020 |
Why?
|
| HL-60 Cells | 1 | 2009 | 32 | 0.020 |
Why?
|
| Tyrosine | 1 | 2010 | 139 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2012 | 809 | 0.020 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2009 | 33 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 151 | 0.020 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2008 | 41 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2009 | 87 | 0.020 |
Why?
|
| Golgi Apparatus | 1 | 2008 | 92 | 0.020 |
Why?
|
| Indoles | 1 | 2009 | 201 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 3716 | 0.020 |
Why?
|
| Polycomb-Group Proteins | 1 | 2007 | 23 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2010 | 508 | 0.020 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2007 | 28 | 0.020 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2007 | 80 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2009 | 595 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3869 | 0.020 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2006 | 38 | 0.010 |
Why?
|
| Cell Extracts | 1 | 2005 | 14 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2007 | 690 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2006 | 333 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2005 | 167 | 0.010 |
Why?
|
| Reference Standards | 1 | 2005 | 229 | 0.010 |
Why?
|
| Streptavidin | 1 | 2004 | 4 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2009 | 1018 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2004 | 108 | 0.010 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2004 | 26 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2004 | 62 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 2004 | 56 | 0.010 |
Why?
|
| Radiation, Ionizing | 1 | 2004 | 39 | 0.010 |
Why?
|
| Biotin | 1 | 2004 | 38 | 0.010 |
Why?
|
| Coloring Agents | 1 | 2004 | 71 | 0.010 |
Why?
|
| G1 Phase | 1 | 2004 | 65 | 0.010 |
Why?
|
| Tyrphostins | 1 | 2003 | 13 | 0.010 |
Why?
|
| Staurosporine | 1 | 2003 | 23 | 0.010 |
Why?
|
| Automation | 1 | 2003 | 65 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2007 | 772 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2004 | 223 | 0.010 |
Why?
|
| Quinazolines | 1 | 2004 | 181 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 2003 | 191 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2003 | 411 | 0.010 |
Why?
|
| Cytosine Deaminase | 1 | 2002 | 15 | 0.010 |
Why?
|
| Avian Sarcoma Viruses | 1 | 2002 | 30 | 0.010 |
Why?
|
| HT29 Cells | 1 | 2002 | 44 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2003 | 229 | 0.010 |
Why?
|
| ErbB Receptors | 1 | 2004 | 295 | 0.010 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2002 | 65 | 0.010 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2001 | 21 | 0.010 |
Why?
|
| Cycloheximide | 1 | 2001 | 41 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2003 | 317 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2001 | 237 | 0.010 |
Why?
|
| Caspases | 1 | 2001 | 157 | 0.010 |
Why?
|
| Pregnancy | 1 | 2013 | 7499 | 0.010 |
Why?
|
| Multigene Family | 1 | 2001 | 290 | 0.010 |
Why?
|
| Logistic Models | 1 | 2005 | 1824 | 0.010 |
Why?
|
| RNA | 1 | 2004 | 517 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 1623 | 0.010 |
Why?
|
| Child | 1 | 2020 | 26214 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2002 | 403 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2002 | 580 | 0.010 |
Why?
|
| DNA | 1 | 2004 | 1413 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 5230 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2009 | 12910 | 0.010 |
Why?
|